Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Shields, Ryan K ^a   Anand, Rohit ^a   Clarke, Lloyd G ^a   Paronish, Julie A ^a   Weirich, Matthew ^a   Perone, Hanna ^a   Kieserman, Jake ^a   Freedy, Henry ^b   Andrzejewski, Christina ^b   Bonilla, Hector ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MERCY HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; COHORT ANALYSIS; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; URINARY TRACT DISEASE ASSESSMENT; VERY ELDERLY; ACUTE KIDNEY INJURY; COMORBIDITY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTOR; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; COMORBIDITY; HUMANS; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 85014773458     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173286     Document Type: Article

References (36)

1. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrobial agents and chemotherapy. 2011; 55(7):3284-94. Epub 2011/05/11. doi:10.1128/AAC.01733-10 PMID: 21555763.
2. Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, et al. Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2015.
3. Dalfino L, Puntillo F, Ondok MJ, Mosca A, Monno R, Coppolecchia S, et al. Colistin-Associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2015; 61(12):1771-7.
4. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011; 53(9):879-84. doi:10.1093/cid/cir611 PMID: 21900484.
5. Omrani AS, Alfahad WA, Shoukri MM, Baadani AM, Aldalbahi S, Almitwazi AA, et al. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Annals of clinical microbiology and antimicrobials. 2015; 14:3. doi:10.1186/s12941-015-0062-8 PMID: 25591721.
6. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. European journal of clinical pharmacology. 2015; 71(7):801-10. doi:10.1007/s00228-015-1865-4 PMID: 26008213.
7. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy. 2011; 31(12):1257-64. doi:10.1592/phco.31.12.1257 PMID: 22122186.
8. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy. 2013; 33(8):812-6. doi:10.1002/phar.1271 PMID: 23606349.
9. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009; 48(12):1724-8. doi:10.1086/599225 PMID: 19438394.
10. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014; 43(4):349-52. doi:10.1016/j.ijantimicag.2013.12.002 PMID: 24439066.
11. Binh NG, Hayakawa K, Co DX, Tuan ND, Anh NH, Thuy NT, et al. The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: Use of colistin in a population of lower body weight. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2015; 35:18-23.
12. Fiaccadori E, Antonucci E, Morabito S, d'Avolio A, Maggiore U, Regolisti G. Colistin Use in Patients With Reduced Kidney Function. American journal of kidney diseases: The official journal of the National Kidney Foundation. 2016; 68(2):296-306.
13. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. American journal of kidney diseases: The official journal of the National Kidney Foundation. 2013; 61(5):649-72.
14. Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Critical care. 2013; 17(1):204. doi:10.1186/cc11454PMID: 23394211.
15. Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-Term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Archives of internal medicine. 2008; 168(6):609- 16. doi:10.1001/archinte.168.6.609 PMID: 18362253.
16. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. Journal of the American Society of Nephrology: JASN. 2005; 16(11):3365-70. doi:10.1681/ASN.2004090740PMID: 16177006.
17. Luo X, Jiang L, Du B, Wen Y, Wang M, Xi X, et al. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. Critical care. 2014; 18(4):R144. doi:10.1186/cc13977 PMID: 25005361.
18. Tanita MT, Carrilho CM, Garcia JP, Festti J, Cardoso LT, Grion CM. Parenteral colistin for the treatment of severe infections: A single center experience. Revista Brasileira de terapia intensiva. 2013; 25 (4):297-305. doi:10.5935/0103-507X.20130051 PMID: 24553511.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. Epub 1976/01/01. PMID: 1244564.
20. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun JB, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clinical practice. 2011; 117(3):c284-8. doi:10.1159/000320746 PMID: 20847571.
21. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrobial agents and chemotherapy. 2010; 54(10):4503-5. doi:10.1128/AAC.01707-09 PMID: 20660694.
22. Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2016.
23. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Critical care. 2013; 17(4):R174. doi:10.1186/cc12853 PMID: 23945197.
24. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. International journal of antimicrobial agents. 2010; 35(5):473-7. doi:10.1016/j.ijantimicag.2009.12.002 PMID: 20089383.
25. Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Critical care. 2010; 14 (2):214. doi:10.1186/cc8855PMID: 20236458.
26. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008; 48(6):2064-77. doi:10.1002/hep.22605 PMID: 19003880.
27. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012; 68(9):1243-55. doi:10.1007/s00228-012-1259-9 PMID: 22411630.
28. O'Hara JA, Ambe LA, Casella LG, Townsend BM, Pelletier MR, Ernst RK, et al. Activities of vancomycin- containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrobial agents and chemotherapy. 2013; 57(5):2103-8. doi:10.1128/AAC.02501-12 PMID: 23422916.
29. Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrobial agents and chemotherapy. 2014; 58(11):6946-8. doi:10.1128/AAC.03776-14 PMID: 25136012.
30. Elefritz JL, Bauer KA, Jones C, Mangino JE, Porter K, Murphy CV. Efficacy and Safety of a Colistin Loading Dose, High-Dose Maintenance Regimen in Critically Ill Patients With Multidrug-Resistant Gram-Negative Pneumonia. Journal of intensive care medicine. 2016.
31. Rigatto MH, Oliveira MS, Perdigao-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Antimicrobial agents and chemotherapy. 2016; 60(4):2443-9. doi:10.1128/AAC.02634-15 PMID: 26856846.
32. Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, et al. Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2016; 62(5):552-8.
33. Ozkan G, Ulusoy S, Orem A, Ersoz S, Alkanat M, Yucesan FB, et al. Protective effect of the grape seed proanthocyanidin extract in a rat model of contrast-induced nephropathy. Kidney & blood pressure research. 2012; 35(6):445-53.
34. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrobial agents and chemotherapy. 2011; 55(9):4044-9. doi:10.1128/AAC.00328-11PMID:21709095.
35. Ghlissi Z, Hakim A, Sila A, Mnif H, Zeghal K, Rebai T, et al. Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environmental toxicology and pharmacology. 2014; 37(3):960-6. doi:10.1016/j.etap.2014.03.004 PMID: 24709323.
36. Samra M, Abcar AC. False estimates of elevated creatinine. Perm J. 2012; 16(2):51-2. PMID: 22745616.